This past April I reported that Vaxart, a small San Francisco vaccine biotech, was ready to start dosing volunteers with its experimental vaccine against norovirus, aka, the stomach flu, in Phase Ib studies (See
Coverage of infectious and chronic diseases — their causes, mechanisms, epidemiology, prevention strategies, and the latest science on how the body fights back.
